Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | LIPA | P38571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8919404 | 0.91 | DGAT1 (0.45) | DGAT1 | |
| SCHEMBL21937394 | 0.82 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL10176834 | 0.78 | DGAT1 (0.38) | DGAT1RIPK1 | |
| SCHEMBL10177484 | 0.78 | DGAT1 (0.38) | DGAT1RIPK1 | |
| SCHEMBL23009522 | 0.76 | DGAT1 (0.43) | DGAT1RIPK1LIPA | |
| SCHEMBL12928711 | 0.75 | DGAT1 (0.41) | DGAT1RIPK1 | |
| SCHEMBL28799046 | 0.74 | DGAT1 (0.44) | DGAT1RIPK1 | |
| SCHEMBL1012654 | 0.74 | DGAT1 (0.34) | DGAT1RIPK1 | |
| SCHEMBL1255240 | 0.74 | SMN1; SMN2 (0.41) | DGAT1RIPK1 | |
| SCHEMBL18745690 | 0.74 | RIPK1 (0.35) | DGAT1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20160303129-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-9303034-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-06-25 | — | — | US | disclosed |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | DGAT1 886/4885RIPK1 4727/4885LIPA 437/4885 |
| US-20100267707-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | DGAT1 3503/4885RIPK1 589/4885LIPA 4589/4885 |
| US-20160303129-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | DGAT1 886/4885RIPK1 4727/4885LIPA 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.